Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ADAMIS PHARMACEUTICALS CORPORATION

(ADMP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Adamis Pharmaceuticals : Announces Proposed Public Offering of Common Stock

09/18/2020 | 08:59am EDT

Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease, announced today that it intends to offer to sell shares of its common stock in an underwritten public offering.

The company expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Raymond James & Associates, Inc. will act as the sole book-running manager for the proposed offering.

The company intends to use the net proceeds from this offering for general corporate purposes, which may include, without limitation, expenditures relating to research, development and clinical trials relating to its products and product candidates, capital expenditures, manufacturing, hiring additional personnel, acquisitions of new technologies or products, the payment, repayment, refinancing, redemption or repurchase of existing or future indebtedness, obligations or capital stock, and working capital.

The securities described above will be offered by the company pursuant to a 'shelf' registration statement on Form S-3 (File No. 333-226100) previously filed with and declared effective by the Securities and Exchange Commission (SEC) on July 18, 2018. A preliminary prospectus supplement and an accompanying prospectus relating to the offering will be filed with the SEC. Electronic copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, from Raymond James & Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716, by telephone at (800) 248-8863, by e-mail at prospectus@raymondjames.com, or by accessing the SEC's website at www.sec.gov.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The company's SYMJEPI (epinephrine) Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. Adamis' naloxone injection product candidate, ZIMHI, for the treatment of opioid overdose is currently under FDA review. Adamis is developing additional products, including treatments for acute respiratory diseases, such as COVID-19, influenza, asthma and COPD. The company's subsidiary, U.S. Compounding, Inc., compounds sterile prescription drugs, and certain nonsterile drugs for human and veterinary use by hospitals, clinics, surgery centers, and vet clinics throughout most of the United States.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the proposed public offering and the intended use of proceeds from the offering and statements about the progress of development of the company's product candidates. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. These forward-looking statements also are subject to risks, uncertainties and assumptions, including those detailed from time to time in the company's filings with the SEC, and represent the company's views only as of the date they are made and should not be relied upon as representing the company's views as of any subsequent date. The company's actual results may differ materially from those contemplated by these forward-looking statements. Except to the extent required by law, the company does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this press release.

Contact:

Tel: 858-997-2400

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about ADAMIS PHARMACEUTICALS CORPORATION
06/14ADAMIS PHARMACEUTICALS  : Files Definitive Proxy Statement and Sends Letter to S..
BU
06/14ADAMIS PHARMACEUTICALS  : Provides Update on Clinical Trial Start-Up Progress fo..
AQ
06/11ADAMIS PHARMACEUTICALS  : Starts Preparation for Clinical Trial on COVID-19 Drug..
MT
06/11Adamis Provides Update on Clinical Trial Start-Up Progress for Tempol in the ..
GL
06/09ADAMIS PHARMACEUTICALS  : FDA Accepts Adamis' Resubmitted New Drug Application f..
MT
06/09Adamis Provides Update on ZIMHI™
GL
06/07ADAMIS PHARMACEUTICALS  : Says NIH Study Found Its Tempol Drug Candidate to be P..
MT
06/07ADAMIS PHARMACEUTICALS  : Highlights National Institute of Health Study Identify..
AQ
06/01ADAMIS PHARMACEUTICALS  : Announces Receipt of Deficiency Letter from Nasdaq (Fo..
PU
06/01ADAMIS PHARMACEUTICALS CORP  : Notice of Delisting or Failure to Satisfy a Conti..
AQ
More news
Financials (USD)
Sales 2021 22,0 M - -
Net income 2021 -24,0 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,68x
Yield 2021 -
Capitalization 144 M 144 M -
Capi. / Sales 2021 6,54x
Capi. / Sales 2022 6,78x
Nbr of Employees 130
Free-Float 99,1%
Chart ADAMIS PHARMACEUTICALS CORPORATION
Duration : Period :
Adamis Pharmaceuticals Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAMIS PHARMACEUTICALS CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price
Last Close Price 0,97 
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers and Directors
NameTitle
Dennis J. Carlo President, Chief Executive Officer & Director
Robert O. Hopkins Chief Financial Officer & Secretary
Richard C. Williams Chairman
Ronald B. Moss Chief Medical Officer
Karen K. Daniels Vice President-Operations
Sector and Competitors
1st jan.Capitalization (M$)
ADAMIS PHARMACEUTICALS CORPORATION99.09%144
JOHNSON & JOHNSON4.52%433 167
ROCHE HOLDING AG11.21%330 710
PFIZER, INC.7.55%221 613
NOVARTIS AG0.77%210 689
ABBVIE INC.8.10%204 582